A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Research output: Contribution to journalReview article

Abstract

Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. This article reviews mechanisms of action and clinical data behind the use of these two commonly used oral hypoglycemic agents with documented efficacy and good safety profile of once-daily administration, alone or in combination with insulin or metformin, in the management of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and impact on vascular health.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems

Keywords

  • Sulfonylurea Compounds: therapeutic use, Thiazolidinediones: therapeutic use, Diabetes Mellitus, Sulfonylurea Compounds: adverse effects, Type 2: drug therapy, Type 2: blood, Blood Glucose: metabolism, Thiazolidinediones: adverse effects
Original languageEnglish
Pages (from-to)721-731
JournalVascular Health and Risk Management
Volume3
Issue number5
Publication statusPublished - 2007
Publication categoryResearch
Peer-reviewedYes

Bibliographic note

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Diabetes and Endocrinology (013241530), Pediatrics/Urology/Gynecology/Endocrinology (013240400)